Get started
Author

Jun Sugisaka

Observed names: J. Sugisaka, Sugisaka J, Sugisaka J., Sugisaka, Jun
ORCID: 0000-0002-1000-0077
Observed ORCID: 0000-0002-1000-0077
OpenAlex ID: A5008558946
Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
2018 · Yukihiro Toi, Shunichi Sugawara, et al. · JAMA Oncology · 354
PDF
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab
2018 · Yukihiro Toi, Shunichi Sugawara, et al. · The Oncologist · 295
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort
2020 · Abdul Rafeh Naqash, Biagio Ricciuti, et al. · Cancer Immunology Immunotherapy · 93
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer
2024 · Yoko Tsukita, Takehiro Tozuka, et al. · JAMA Oncology · 72
PDF
CLCA2, a target of the p53 family, negatively regulates cancer cell migration and invasion
2012 · Yasushi Sasaki, Ryota Koyama, et al. · Cancer Biology & Therapy · 59
PDF
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer
2019 · Mari Aso, Yukihiro Toi, et al. · The Oncologist · 57
PDF
Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab
2019 · Jun Sugisaka, Yukihiro Toi, et al. · JMA Journal · 24
Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC
2025 · Kentaro Tanaka, Jun Sugisaka, et al. · Nature Communications · 23
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer
2024 · Ryota Shibaki, Daichi Fujimoto, et al. · Journal for ImmunoTherapy of Cancer · 22
PDF
Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer
2021 · Kana Ono, Hirotaka Ono, et al. · Cancer Medicine · 19
First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057).
2023 · Mao Uematsu, Yoko Tsukita, et al. · Journal of Clinical Oncology · 12
Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers
2021 · Tomoiki Aiba, Chieko Hattori, et al. · PLoS ONE · 10
PDF
Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study.
2019 · Yukihiro Toi, Yuichiro Kimura, et al. · Sarcoidosis vasculitis and diffuse lung diseases · 9
PDF
Durvalumab after chemoradiotherapy in non‐small cell lung cancer with EGFR mutation: A real‐world study ( HOT2101 )
2024 · Kosuke Tsuji, Hidenori Mizugaki, et al. · Cancer Science · 8
PDF
Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism
2020 · Takamasa Hotta, Yukari Tsubata, et al. · Respiratory Investigation · 8
Array-based genome-wide RNAi screening to identify shRNAs that enhance p53-related apoptosis in human cancer cells
2014 · Masashi Idogawa, Tomoko Ohashi, et al. · Oncotarget · 7
PDF
Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial
2025 · Tetsuhiko Asao, Yu Saida, et al. · The Lancet Respiratory Medicine · 5
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study
2024 · Jun Sugisaka, Daichi Fujimoto, et al. · Lung Cancer · 5
Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non–small‐cell lung cancer ( NEJ056 )
2024 · Megumi Furuta, Hidehito Horinouchi, et al. · Cancer Science · 4
PDF
Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy‐Induced Cytokine Release Syndrome
2024 · Soichiro Minami, Yosuke Kawashima, et al. · Cancer Reports · 4
PDF
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort
2020 · Abdul Rafeh Naqash, Biagio Ricciuti, et al. · Cancer Immunology Immunotherapy · 4
PDF
Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
2019 · J. Sugisaka, S. Sugawara, et al. · Annals of Oncology · 4
PDF
A multicenter, randomized, controlled, open-label trial to determine the optimal duration of steroid therapy for mild pneumonitis associated with immune checkpoint inhibitors.
2025 · Daichi Fujimoto, Mitsuhiro Abe, et al. · Journal of Clinical Oncology · 3
PDF
Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial
2026 · Daichi Fujimoto, Mitsuhiro Abe, et al. · American Journal of Respiratory and Critical Care Medicine · 2
Efficacy and safety of immune checkpoint inhibitors in advanced non-small cell lung cancer with idiopathic interstitial pneumonia or interstitial lung abnormalities: NJLCG2301
2025 · Fumihiko Okumura, Hisashi Tanaka, et al. · Translational Lung Cancer Research · 2
Works count: 66
Citation count: 1,114
H-index: 11
I10-index: 12
Year
Topic
Type